| Date |
Title |
|
| November 17, 2020, Clinical Trial Results TV |
Dr. John Teerlink and Dr. C. Michael Gibson Discuss: Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction |
| November 13, 2020, Scrip |
Cytokinetics Sees Omecamtiv Potential In Certain Heart Failure Patients |
| November 13, 2020, BioCentury |
Cytokinetics sees path to market for omecamtiv mecarbil in more severe heart failure patients |
| November 13, 2020, Cardiology Today |
Omecamtiv mecarbil lowers CV death/HF events in HFrEF: GALACTIC-HF |
| November 10, 2020, CEO Magazine |
The long, patient journey: Robert Blum |
| August 20, 2020, CNBC Fast Money |
Under-the-radar biotech name is up 120% this year |
| July 14, 2020, Endpoints News |
Cytokinetics nabs Chinese partner, up to $450M as CV becomes company focus |
| July 14, 2020, San Francisco Business Times |
Biotech legends help launch parasite-fighting startup with deep Stanford ties |
| March 5, 2020, ALS News Today |
Reldesemtiv Wins EMA Orphan Drug Designation for ALS Treatment |
| December 19, 2019, ALS News Today |
Reldesemtiv Earns FDA’s Orphan Drug Designation for ALS Treatment |
| December 10, 2019, Healio |
COSMIC-HF: Omecamtiv mecarbil may improve diastolic function, pulmonary pressures in HF |
| December 9, 2019, ALS News Today |
Reldesemtiv Effects Maintained When Used on Top of Rilutek or Radicava, New Trial Analysis Shows |
| November 25, 2019, Forbes |
As Boomers Age, We Need New Medical Approaches To Heart Disease |
| |
|
| |
|
